XERIS BIOPHARMA HOLDINGS, INC. Earnings Per Share (Basic)
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Earnings Per Share (Basic) of -$0.18 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-06
- XERIS BIOPHARMA HOLDINGS, INC. earnings per share, basic for the quarter ending 2026-06-30 was -$0.18.
- XERIS BIOPHARMA HOLDINGS, INC. earnings per share, basic for the quarter ending 2026-03-31 was $0.01.
- XERIS BIOPHARMA HOLDINGS, INC. earnings per share, basic for the quarter ending 2025-12-31 was $0.07.
- XERIS BIOPHARMA HOLDINGS, INC. earnings per share, basic for the quarter ending 2025-09-30 was $0.00.
- XERIS BIOPHARMA HOLDINGS, INC. earnings per share, basic for fiscal 2025 was $0.00.
- XERIS BIOPHARMA HOLDINGS, INC. earnings per share, basic for fiscal 2024 was -$0.37.
- XERIS BIOPHARMA HOLDINGS, INC. earnings per share, basic for fiscal 2023 was -$0.45.
- XERIS BIOPHARMA HOLDINGS, INC. earnings per share, basic for fiscal 2022 was -$0.70.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.18 10-Q · filed 2026-08-06 | -$0.17 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $0.01 10-Q · filed 2026-05-07 | $0.08 derived: net income ÷ weighted average shares · filed 2026-05-07 | $0.08 derived: net income ÷ weighted average shares · filed 2026-05-07 | |
| 2025-12-31 | $0.07 derived: net income ÷ weighted average shares · filed 2026-03-02 | $0.07 derived: net income ÷ weighted average shares · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 | |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | -$0.07 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | -$0.01 10-Q · filed 2026-08-06 | -$0.07 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | -$0.06 10-Q · filed 2026-05-07 | -$0.10 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$0.20 derived: net income ÷ weighted average shares · filed 2026-05-07 | |
| 2024-12-31 | -$0.03 derived: net income ÷ weighted average shares · filed 2026-03-02 | -$0.14 derived: net income ÷ weighted average shares · filed 2026-03-02 | -$0.37 10-K · filed 2026-03-02 | |
| 2024-09-30 | -$0.11 10-Q · filed 2025-11-06 | -$0.34 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | -$0.10 10-Q · filed 2025-08-07 | -$0.24 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | -$0.14 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | -$0.45 10-K · filed 2026-03-02 | |||
| 2023-09-30 | -$0.09 10-Q · filed 2024-11-08 | -$0.36 10-Q · filed 2024-11-08 | ||
| 2023-06-30 | -$0.14 10-Q · filed 2024-08-08 | -$0.27 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | -$0.12 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | -$0.70 10-K · filed 2025-03-06 | |||
| 2022-09-30 | -$0.16 10-Q · filed 2023-11-09 | -$0.60 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | -$0.19 10-Q · filed 2023-08-08 | -$0.44 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | -$0.25 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | -$1.55 10-K · filed 2024-03-06 | |||
| 2021-09-30 | -$0.39 10-Q · filed 2022-11-09 | -$1.11 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | -$0.41 10-Q · filed 2022-08-10 | -$0.72 10-Q · filed 2022-08-10 | ||
| 2021-03-31 | -$0.30 10-Q · filed 2022-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |